Immunopharmacology Comments |
Tregalizumab was designed to selectively activate Treg cells and boost their function to mediate an increase in their immunosuppressive activity [1-2]. |
Immunopharmacology Disease | |||
Disease | X-Refs | Comment | References |
Rheumatoid arthritis |
Disease Ontology:
DOID:7148 OMIM: 180300 |
Tregalizumab failed to show clinical efficacy in Phase 2 trial (NCT01999192), and development was discontinued. | 3 |